Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy
NCT00108108 · Novartis Pharmaceuticals · PHASE1 · terminated · last registry update 2012-10-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow enrollment and minimal preliminary biological and clinical efficacy.” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD40 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2013-06-24Phase 3 first posted: Bio Products Laboratory, Subgam (NCT01884311)
- 2012-10-31Results posted on the registry: Hoffmann-La Roche, Paclitaxel + Carboplatin + CP-870,893 + Paclitaxel + Carboplatin + CP-870,893 (NCT00607048)
- 2012-05-21Also stopped (withdrawn): Baylor College of Medicine, IL-2 secreting and hCL4OL-expressing autologous B-CLL cells + IL-2 (NCT00224354)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision